Skip to content

Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.

The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00272428
Enrollment
13000
Registered
2006-01-06
Start date
1994-10-31
Completion date
2005-09-30
Last updated
2009-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Prevention trial, Antioxydant vitamins and minerals, Cancer, Ischemic disease, Mortality, Health related quality of life

Brief summary

It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.

Detailed description

From experimental studies it is known that free radicals may induce numerous pathological processes, and it has been suggested that, because of their antioxidant capacity, nutrients such as beta-carotene, vitamin C, vitamin E, selenium and zinc may prevent such harmful effects. Epidemiological data from cross-sectional, case-control, and prospective studies have indeed shown a strong relationship between the intake of antioxidant vitamins and minerals, or foods rich in these nutrients, and the risk of cancer and ischaemic cardiovascular diseases (CVD). However, randomised placebo-controlled primary prevention trials, in which antioxidant micronutrients alone or in pairs were given at high doses over long periods, have not been able to prove this potential beneficial effect, and two of these even suggested harmful effects. The seemingly contradictory results between the observational studies and these randomised trials can be explained by the fact that the doses used in clinical trials were much higher than the highest levels reachable by usual dietary intake which have been found to be associated in observational studies with the lowest risk of cancer and CVD. In fact, the only trial which did observe a beneficial effect on total mortality and cancer incidence used nutritional doses of a combination of several vitamins and minerals and was performed on Chinese population with very low baseline micronutrient status, due to poor life conditions in this region (9). The objective of the SUpplementation en VItamines et Minéraux AntioXydants (SU.VI.MAX) study, was to test in a randomised, placebo-controlled trial, if an adequate and well balanced intake of antioxidant nutrients reduces the incidence of cancers and ischaemic cardiovascular diseases in a middle-age general population.

Interventions

BEHAVIORALascorbic acid, vitamin E, beta carotene, selenium, zinc

Sponsors

French private agencies
CollaboratorUNKNOWN
Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* women aged 35-60 years, men aged 45-60 years * acceptance of the possibility to be given a placebo and acceptance of the constraints of participation * lack of previous regular supplementation with any of the vitamins or minerals in the supplement provided * absence of extreme beliefs or behavior regarding diet

Exclusion criteria

* disease likely to hinder active participation or threatened 5-year survival

Design outcomes

Primary

MeasureTime frame
Major fatal and non fatal ischemic cardiovascular events
Cancer any kind except for basal cell skin carcinoma

Secondary

MeasureTime frame
Health-related quality of life
Intermediate criteria of anthropometric status
Intermediate criteria of biological status
Intermediate criteria of clinical status
All cause mortality

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026